Personalis, INC 10-Q quarterly reports

Personalis, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a 30% revenue increase driven by clinical diagnostic growth, but also reporting substantial net losses and ongoing operational risks, all while navigating a pending acquisition by Tempus AI.

Personalis, Inc. reported a significant 44% year-over-year revenue decline in Q3 2025, primarily driven by reduced Natera volumes and population sequencing, despite strong growth in clinical diagnostic tests and strategic partnership expansions.

Personalis, Inc. reported a 24% decrease in second-quarter 2025 revenue and a widened net loss, driven by a significant decline in enterprise sales from a major customer, despite growth in clinical diagnostic and population sequencing segments.

Personalis, Inc. announces a 6% increase in revenue for Q1 2025, driven by growth in pharma tests and services and population sequencing, while highlighting progress in clinical diagnostics and key partnerships.

Personalis Inc. saw a 41% increase in revenue in Q3 2024, primarily driven by a 96% surge in pharma test revenue, while also securing significant financing.

Personalis Inc. saw a 35% increase in total revenue in the second quarter of 2024, primarily driven by a significant rise in pharma testing revenue.

Personalis Inc. saw a modest revenue increase in the first quarter of 2024, driven by growth in pharma testing, while continuing to focus on expanding its clinical diagnostics business.